Cargando…
A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are com...
Autores principales: | Liu, Yixin, Zhang, Zheyang, Li, Tianhao, Li, Xin, Zhang, Sainan, Li, Ying, Zhao, Wenyuan, Gu, Yunyan, Guo, Zheng, Qi, Lishuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813654/ https://www.ncbi.nlm.nih.gov/pubmed/31681618 http://dx.doi.org/10.3389/fonc.2019.01094 |
Ejemplares similares
-
An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016) -
Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer
por: Wang, Wei, et al.
Publicado: (2019) -
Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
por: Li, Ying, et al.
Publicado: (2020) -
An individualized gene expression signature for prediction of lung adenocarcinoma metastases
por: Qi, Lishuang, et al.
Publicado: (2017) -
TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)